Cancer Biological Therapy Market: Dynamics
The factors such as growing prevalence of cancer, continuous patent expiry of cancer drugs, rising impact of biosimilars and increasing demand of biological and targeted drug therapies will drive the overall cancer biological therapy market. According to WHO, the number of new cancer cases is projected to rise 70% in the coming two decades, mainly due to increased use of tobacco and alcohol consumption.
However, the threat of failure in treatment, the high cost of drug development, the adverse effects of cancer drug therapy, particularly chemotherapy and stricter government regulations will hinders the overall cancer biological therapy market growth globally.
Get Sample Free Sample of this Premium Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-2044
The immune system protects a person from infection and disease. The Biological therapies are used to lessen the spread and lower the risk of recurrence for some cancers, slow the growth, control symptoms of cancer, deliver radioactive substances or chemotherapy drugs directly to a tumour lessen and some of the side effects from cancer treatments.
Biological cancer therapies use the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. It is also called biotherapy or biological response modifiers. Interferons and monoclonal antibodies are among the most promising biological approaches to cancer treatment. Biological therapy works by stimulating, boosting, restoring or acting like the body’s immune system response against cancer cells. Cancer is a leading cause of death worldwide.
Factors that contribute to geographic differences in cancer occurrence include the prevalence of risk factors, the availability and use of diagnostic tests, variations in the age structure of the population, and the availability and quality of treatment. According to WHO, approximately 14 million new cases and 8.2 million cancer related deaths in 2012. Tobacco use is the most important risk factor for cancer causing around 20% of global cancer deaths and around 70% of global lung cancer deaths.
Talk to Analyst: https://www.futuremarketinsights.com/ask-question/rep-gb-2044
Cancer Biological Therapy Market: Regional Overview
Geographically, the market is dominated by North America, followed by Europe, Asia Pacific. Growth in the North American segment is primarily driven by presence of large number of cancer biological drug and vaccine manufacturers, increasing disposable income, affordable cancer treatment facility and growing number of health insurance coverage for life-threatening diseases.
According to National Cancer Institute (NCI) an estimated 16, 85,210 new cases will be diagnosed in 2016, in the US. Europe is the second largest market .Asia pacific is expected to grow at a highest rate due to increasing prevalence of cancer patient, better healthcare facilities and growing number of insurance coverage. Japan contributes largest share in cancer treatment market in Asia Pacific due to high prevalence of cancer in Japanese population.
Some of the major players operating in the market for Cancer Biological Therapy Market are F. Hoffmann-La Roche AG, Novartis International AG, Merck & Co., Inc., Amgen Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and others.
Buy this Report Now: https://www.futuremarketinsights.com/checkout/2044
The report covers exhaustive analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
- Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
- Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Cancer Biological Therapy Market: Segmentation
The global Cancer Biological Therapy market is classified on the basis of Product type, distribution channels and regional presence.
Segmentation based on product type:
- Vaccines
- Cancer growth blockers
- Tyrosine kinase inhibitors
- Proteasome inhibitors
- mTOR inhibitors
- Monoclonal antibodies
- Naked monoclonal antibodies
- Conjugated monoclonal antibodies
- Bispecific monoclonal antibodies
- Cytokines
- Interferons
- Interleukins
- Blood cell growth factors
- Lenograstim
- Filgrastim
- Gene therapy
Segmentation based on distribution channels:
- Hospital pharmacies
- Retail pharmacies
- Mail order pharmacies
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs